The role of nasal IgA in children vaccinated with live attenuated influenza vaccine

被引:96
作者
Ambrose, Christopher S. [1 ]
Wu, Xionghua [1 ]
Jones, Taff [2 ]
Mallory, Raburn M. [1 ]
机构
[1] MedImmune LLC, Gaithersburg, MD 20878 USA
[2] MedImmune LLC, Mountain View, CA USA
关键词
IgA; Nasal IgA; Influenza; Live attenuated influenza vaccine; Children; CULTURE-CONFIRMED INFLUENZA; CELLULAR IMMUNE-RESPONSES; YOUNG-CHILDREN; RELATIVE EFFICACY; VIRUS-INFECTION; TRIVALENT; SAFETY; IMMUNOGENICITY; PROTECTION; ADULTS;
D O I
10.1016/j.vaccine.2012.09.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Background: Immunoglobulin A (IgA) is the predominant antibody produced in response to mucosal infections. The role of IgA in providing protection against influenza in children vaccinated with live attenuated influenza vaccine (LAIV) has not been well described. Methods: Nasal IgA responses were assessed using data from 3 prospective, 2-year, randomized studies comparing LAIV with placebo in children 6-36 months of age. In each study, samples were collected in a subset of patients; a new cohort was enrolled each year. Ratios of strain-specific nasal IgA to total nasal IgA were calculated and prevaccination to postvaccination geometric mean fold-rises (GMFRs) were evaluated. Mean postvaccination IgA ratios were compared for subjects with and without confirmed influenza illness by study and in pooled analyses. Results: Across studies, a higher percentage of children receiving LAIV had a >= 2-fold increase in strain-specific IgA ratio compared with placebo recipients. GMFRs after LAIV in years 1 and 2 ranged from 1.2 to 6.2, compared with 0.5-2.2 among placebo recipients. Similar responses were observed in subjects who were baseline seronegative and seropositive based on serum hemagglutination inhibition antibody titers. In years 1 and 2, the mean postvaccination strain-specific to total IgA ratio was 3.1-fold (P < 0.01) and 2.0-fold (P < 0.03) higher among LAIV recipients with no evidence of culture-confirmed influenza illness compared with LAIV recipients who developed culture-confirmed influenza illness; a similar and consistent trend was observed for each individual study and type/subtype. Conclusions: The current analysis demonstrates that nasal IgA contributes to the efficacy of LAIV and can provide evidence of vaccine-induced immunity. However, the inherent heterogeneity in nasal antibody levels and variability in nasal specimen collection hinders the precise evaluation of mucosal antibody responses. Other studies have demonstrated that LAIV-induced immunity is also partially explained by T-cell immunity, serum antibody responses, and innate immunity, consistent with the multi-faceted nature of immunity induced by wild-type influenza infection and other live virus vaccines. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6794 / 6801
页数:8
相关论文
共 50 条
[1]
The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies [J].
Ambrose, Christopher S. ;
Wu, Xionghua ;
Knuf, Markus ;
Wutzler, Peter .
VACCINE, 2012, 30 (05) :886-892
[2]
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults [J].
Ambrose, Christopher S. ;
Levin, Myron J. ;
Belshe, Robert B. .
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2011, 5 (02) :67-75
[3]
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections [J].
Ashkenazi, Shai ;
Vertruyen, Andre ;
Aristegui, Javier ;
Esposito, Susanna ;
McKeith, David Douglas ;
Klemola, Timo ;
Biolek, Jiri ;
Kuehr, Joachim ;
Bujnowski, Tadeusz ;
Desgrandchamps, Daniel ;
Cheng, Sheau-Mei ;
Skinner, Jonathan ;
Gruber, William C. ;
Forrest, Bruce D. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (10) :870-879
[4]
Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin [J].
Basha, Saleem ;
Hazenfeld, Staci ;
Brady, Rebecca C. ;
Subbramanian, Ramu A. .
HUMAN IMMUNOLOGY, 2011, 72 (06) :463-469
[5]
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [J].
Belshe, RB ;
Mendelman, PM ;
Treanor, J ;
King, J ;
Gruber, WC ;
Piedra, P ;
Bernstein, DI ;
Hayden, FG ;
Kotloff, K ;
Zangwill, K ;
Iacuzio, D ;
Wolff, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1405-1412
[6]
Live attenuated versus inactivated influenza vaccine in infants and young children [J].
Belshe, Robert B. ;
Edwards, Kathryn M. ;
Vesikari, Timo ;
Black, Steven V. ;
Walker, Robert E. ;
Hultquist, Micki ;
Kemble, George ;
Connor, Edward M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07) :685-696
[7]
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age [J].
Block, Stan L. ;
Yogev, Ram ;
Hayden, Frederick G. ;
Ambrose, Christopher S. ;
Zeng, Wen ;
Walker, Robert E. .
VACCINE, 2008, 26 (38) :4940-4946
[8]
Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy Subjectsdel [J].
Block, Stan L. ;
Reisinger, Keith S. ;
Hultquist, Micki ;
Walker, Robert E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4001-4008
[9]
Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children [J].
Block, Stan L. ;
Falloon, Judith ;
Hirschfield, Jeffrey A. ;
Krilov, Leonard R. ;
Dubovsky, Filip ;
Yi, Tingting ;
Belshe, Robert B. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (07) :745-751
[10]
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults [J].
Block, Stan L. ;
Yi, Tingting ;
Sheldon, Eric ;
Dubovsky, Filip ;
Falloon, Judith .
VACCINE, 2011, 29 (50) :9391-9397